EGFR and metastatic neoplasm: Additionally, we demonstrated that the male gender, initial metastatic disease, adrenal metastasis, and the absence of intrathoracic metastasis impacted PFS negatively in patients with EGFRm mNSCLC who received EGFR-TKI treatment in the present study.